Acurx Pharmaceuticals Files 8-K
Ticker: ACXP · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1736243
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K on 3/18/24 for financial updates.
AI Summary
Acurx Pharmaceuticals, Inc. filed an 8-K on March 18, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This filing indicates Acurx Pharmaceuticals is providing updates on its financial status and operational results to the SEC. Investors should review the full filing for specific details.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not inherently present new risks.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- March 18, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40536 (other) — Commission File Number
- 259 Liberty Avenue, Staten Island, NY 10305 (address) — Address of principal executive offices
- ( 917 ) 533-1469 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Acurx Pharmaceuticals, Inc.'s results of operations and financial condition, as well as to provide financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 18, 2024.
In which state is Acurx Pharmaceuticals, Inc. incorporated?
Acurx Pharmaceuticals, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The company's principal executive office is located at 259 Liberty Avenue, Staten Island, NY 10305.
What is the registrant's telephone number?
The registrant's telephone number is (917) 533-1469.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-03-18 16:15:37
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ACXP The Nasdaq Stock Mar
Filing Documents
- tm249120d1_8k.htm (8-K) — 25KB
- tm249120d1_ex99-1.htm (EX-99.1) — 56KB
- tm249120d1_img001.jpg (GRAPHIC) — 2KB
- 0001104659-24-035556.txt ( ) — 263KB
- acxp-20240318.xsd (EX-101.SCH) — 3KB
- acxp-20240318_lab.xml (EX-101.LAB) — 33KB
- acxp-20240318_pre.xml (EX-101.PRE) — 22KB
- tm249120d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On March 18, 2024, Acurx Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023 and providing a business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated March 18, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized. Acurx Pharmaceuticals, Inc. Date: March 18, 2024 By: /s/ David P. Luci Name: David P. Luci Title: President and Chief Executive Officer